<DOC>
	<DOCNO>NCT00238355</DOCNO>
	<brief_summary>RATIONALE : Voriconazole caspofungin acetate may control invasive fungal infection patient weaken immune system . PURPOSE : This phase II trial study well give voriconazole together caspofungin acetate work treat invasive fungal infection patient weaken immune system .</brief_summary>
	<brief_title>Voriconazole Caspofungin Acetate Treating Invasive Fungal Infections Patients With Weakened Immune Systems</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 12-week complete partial response rate immunocompromised patient invasive fungal infection treat voriconazole caspofungin acetate . Secondary - Determine 12-week survival rate patient treat regimen . - Determine safety regimen patient . OUTLINE : Patients receive voriconazole orally IV 1 hour twice daily caspofungin acetate IV 1 hour daily day 1-84 . Treatment continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 47 patient accrue study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis probable definite invasive fungal infection 1 follow organism : Aspergillus specie Fusarium specie Scedosporium specie ( Pseudallescheria boydii ) Other dematiaceous mold The following diagnosis allow : Zygomycetes ( Mucor Rhizopus specie ) Chronic aspergillosis Aspergilloma Allergic bronchopulmonary aspergillosis Must immunocompromised PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy At least 72 hour Hematopoietic Not specify Hepatic AST &lt; 5 time upper limit normal ( ULN ) Bilirubin &lt; 5 time ULN Alkaline phosphatase &lt; 5 time ULN No ChildPugh class C cirrhosis Renal Creatinine clearance ≥ 50 mL/min Pulmonary No mechanical ventilation Other Not pregnant nursing Fertile patient must use effective contraception No hypersensitivity azoles , caspofungin acetate , components No history galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 14 day since prior therapeutic antifungal therapy ≥ 1 week duration More 14 day since prior concurrent administration follow medication : Terfenadine Astemizole Cisapride Pimozide Quinidine Sirolimus Rifampin Carbamazepine Longacting barbiturates Rifabutin Ergot alkaloid ( i.e. , ergotamine dihydroergotamine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>infection</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>